INHIBRX BIOSCIENCES, INC. Increase (Decrease) in Prepaid Expense and Other Assets
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $692.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$371.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.06M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$423.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$25.00K.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.40M.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$2.98M, a 128.99% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $10.29M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $692.00K 10-Q · filed 2026-08-13 | $269.00K derived: sum of 3 quarters · filed 2026-08-13 | $244.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-14 | $640.00K derived: sum of 2 quarters · filed 2026-05-14 | $615.00K derived: sum of 3 quarters · filed 2026-05-14 | $393.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$448.00K derived: sum of 2 quarters · filed 2026-03-19 | -$670.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.40M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$247.00K derived: sum of 2 quarters · filed 2026-08-13 | -$977.00K 10-Q · filed 2025-11-14 | -$3.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$952.00K 10-Q · filed 2026-08-13 | -$3.56M derived: sum of 3 quarters · filed 2026-08-13 | -$7.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$730.00K 10-Q · filed 2026-05-14 | -$3.33M derived: sum of 2 quarters · filed 2026-05-14 | -$7.16M derived: sum of 3 quarters · filed 2026-05-14 | -$6.07M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$6.43M derived: sum of 2 quarters · filed 2026-03-19 | -$5.34M derived: sum of 3 quarters · filed 2026-03-19 | -$2.98M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$3.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.74M derived: sum of 2 quarters · filed 2025-11-14 | -$377.00K 10-Q · filed 2025-11-14 | -$9.36M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.45M 10-Q · filed 2025-08-13 | -$5.54M derived: sum of 3 quarters · filed 2025-08-13 | $9.60M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $2.36M 10-Q · filed 2025-05-14 | -$6.62M derived: sum of 2 quarters · filed 2025-05-14 | $8.52M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $6.15M derived: sum of 2 quarters · filed 2025-03-17 | $10.29M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $15.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $19.27M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $4.13M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |